company background image
BRTX logo

BioRestorative Therapies NasdaqCM:BRTX Stock Report

Last Price

US$1.52

Market Cap

US$10.7m

7D

4.1%

1Y

-13.0%

Updated

23 Dec, 2024

Data

Company Financials +

BioRestorative Therapies, Inc.

NasdaqCM:BRTX Stock Report

Market Cap: US$10.7m

BRTX Stock Overview

Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. More details

BRTX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

BioRestorative Therapies, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BioRestorative Therapies
Historical stock prices
Current Share PriceUS$1.52
52 Week HighUS$3.67
52 Week LowUS$1.03
Beta62.37
1 Month Change2.70%
3 Month Change-17.38%
1 Year Change-13.04%
3 Year Change-67.31%
5 Year Change-94.41%
Change since IPO-100.00%

Recent News & Updates

Recent updates

BioRestorative begins enrollment in mid-stage study of stem cell therapy for lumbar disk disease

Jun 30

Shareholder Returns

BRTXUS BiotechsUS Market
7D4.1%-3.8%-2.7%
1Y-13.0%-2.6%23.4%

Return vs Industry: BRTX underperformed the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: BRTX underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is BRTX's price volatile compared to industry and market?
BRTX volatility
BRTX Average Weekly Movement7.2%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: BRTX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BRTX's weekly volatility has decreased from 16% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a11Lance Alstodtwww.biorestorative.com

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs relate to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue.

BioRestorative Therapies, Inc. Fundamentals Summary

How do BioRestorative Therapies's earnings and revenue compare to its market cap?
BRTX fundamental statistics
Market capUS$10.73m
Earnings (TTM)-US$9.65m
Revenue (TTM)US$377.00k

27.9x

P/S Ratio

-1.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BRTX income statement (TTM)
RevenueUS$377.00k
Cost of RevenueUS$24.73k
Gross ProfitUS$352.27k
Other ExpensesUS$10.00m
Earnings-US$9.65m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.39
Gross Margin93.44%
Net Profit Margin-2,558.95%
Debt/Equity Ratio0%

How did BRTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 01:38
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioRestorative Therapies, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael OkunewitchMaxim Group
Elemer PirosRoth MKM
Jonathan AschoffRoth MKM